The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease

European Respiratory Journal

Volumn 45, Issue 4, 2015, Pages 1177-1179

  Winthrop, Kevin L ^a   Ku, Jennifer H ^a   Marras, Theodore K ^b   Griffith, David E ^c   Daley, Charles L ^d   Olivier, Kenneth N ^e   Aksamit, Timothy R ^f   Varley, Cara D ^a   Mackey, Katherine ^a   Prevots, D Rebecca ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS AT TYLER   (United States)

^d DEPARTMENT OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; LINEZOLID; MACROLIDE; PYRIDOXINE; QUINOLONE DERIVATIVE; RIFAMPICIN; ANTIINFECTIVE AGENT;

AGED; ANEMIA; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; CHILD; COHORT ANALYSIS; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM CHELONAE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT WITHDRAWAL; VITAMIN SUPPLEMENTATION; ADOLESCENT; ADULT; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG TOLERANCE; FOLLOW UP; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LINEZOLID; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926443279     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00169114     Document Type: Letter

References (14)

1. Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in US medicare beneficiaries. Am J Respir Crit Care Med 2012; 185: 881-886.
2. CDC. Reported tuberculosis in the United States, 2012. Atlanta, US Department of Health and Human Services, 2013.
3. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
4. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
5. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
6. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
7. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
8. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
9. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009; 59: Suppl. 1, S59-S74.
10. Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50: 1599-1602.
11. Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67: 1503-1507.
12. Rey-Jurado E, Tudo G, de la Bellacasa JP, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2013; 41: 278-280.
13. Guna R, Munoz C, Dominguez V, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of mycobacterium kansasii. J Antimicrob Chemother 2005; 55: 950-953.
14. Wallace RJJr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45: 764-767.